Keratoacanthoma
☆ Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Typysk Keratoacanthoma
References
Keratoacanthoma (KA) is in faak hûdtumor bekend om syn rappe groei en mooglikheden om op himsels werom te gean. It komt typysk foar yn âldere, fair-skinned manlju mei in skiednis fan sinne skea. Wylst sjirurgyske ferwidering mei excision of Mohs mikrografyske sjirurgy de gewoane behanneling is, binne d'r ferskate oare terapyopsjes beskikber.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is in leechgradige tumor dy't begjint yn bepaalde klieren yn 'e hûd en liket op squamous cell carcinoma (SCC) ûnder in mikroskoop. D'r is oanhâldend debat oer oft KA moat wurde klassifisearre as in foarm fan invasive SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) is de op ien nei meast foarkommende soarte kanker by minsken, foaral ûnder âldere persoanen. Surgery wurdt typysk brûkt om cSCC te behanneljen, mar foar guon pasjinten dy't gjin sjirurgy kinne hawwe of kieze net, kinne oare opsjes lykas intralesionale behannelingen wurde beskôge. Tradysjonele intralesionale behannelingen (methotrexate or 5-fluorouracil) binne brûkt, mar d'r is oanhâldend ûndersyk nei nije oanpakken lykas intralesionale immunotherapy en onkolytyske viroterapy. Hjiryn sille wy sjen nei ferskate intralesionale behannelingen foar cSCC, fariearjend fan klassike metoaden oant moderne strategyen.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Under de mikroskoop liket keratoacanthoma tige op squamous cell carcinoma. Wylst guon patologen keratoacanthoma klassifisearje as in ûnderskate entiteit en net as in maligniteit, giet sa'n 6% fan klinyske en histologyske keratoacanthoma foarút nei invasive en agressive plaveiselkankers.
○ Diagnose en behanneling
#Dermoscopy
#Skin biopsy